SLC16A1 and colorectal cancer: An example of specifically targeting a colorectal cancer metabolic adaptation is 3-bromopyruvate sensitivity, taking advantage that the colorectal cancer cells present overexpression of MCT1, induced by the Wnt pathway [89,126].